Kiora Pharmaceuticals To Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference; Online Presentation Will Be Available August 17, 2022 at 7:00 am EST

Salt Lake City, Utah--(August 9, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced it will participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference.


The Company’s presentation will be available on-demand from the Investor Relations section of Kiora’s website ( on August 17, 2022, starting at 7:00 am Eastern Daylight Time. The presentation will be archived on the Kiora’s website for 90 days.


About Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid Arthritis ("OPRA"). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase ("DHODH") with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.

In addition to news releases and SEC filings, we expect to post information on our website,, and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.


Investor Contact
Francina Agosti, PhD
(617) 546-0742